axitinib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 2 (1)

Interventional (1)

Maria Sklodowska-Curie Institute - Oncology Center (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadmeasurable disease

I am/have/hadhypertension

I am/have/hadmetastasis

I am/have/hadneutrophil count

I am/have/hadunstable angina

I am/have/hadplatelet count

I am/have/hadangina

I am/have/hadmyocardial infarction

I am/have/haddiastolic blood pressure

I am/have/hadsystolic blood pressure

I am/have/hadffpe

I am/have/hadstroke

I am/have/hadimmunohistochemistry

I am/have/hadcongestive heart failure

I am/have/hadglomerular filtration rate

I am/have/hadlymphocyte count

I am/have/hadinternational normalized ratio (inr)

I am/have/hadcardiovascular disease

I am/have/hadaptt

I am/have/hadthromboplastin

added new label for I am/have/had

more

I am looking for

I am looking foraxitinib

I am looking foravelumab

I am looking forsunitinib

I am looking forcombined oral contraceptives

I am looking forimatinib

I am looking foranticoagulants

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy

To assess anti-tumor activity of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression on second or third line treatment (after failure on at least of imatinib and sunitinib) in terms of progression-free survival (PFS)

glomerular filtration rate

immunohistochemistry

stromal tumor

avelumab

gastrointestinal stromal tumor

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.